论文部分内容阅读
在自身免疫和全身炎性疾病中,对静脉用混合IgG制剂(IVIg)显示出具有抗补体活性。无论在体内还是体外,IVIg是活化的C4和C3的优先受体,从而由靶表面转移补体活性。作者探讨了在补体-细菌相互作用中IVIg的影响,以图确定有关对细菌的自然免疫中IVIg制剂的安全性,并拓展在IVIg生理作用机理方面的知识。作者使用对补体敏感和补体抗性菌株,研究了IVIg对C3结合在细菌表面的作用。在所有的情况下,是否通过经典的或改变的旁路补体可能被细菌直接激活,IVIg均对结合在细菌上的C3总量无影响。另外,IVlg亦不抑制补体依
In autoimmune and systemic inflammatory diseases, intravenous mixed IgG preparations (IVIg) showed anti-complement activity. IVIg is a preferential receptor of activated C4 and C3 both in vivo and in vitro, thereby transferring complement activity from the target surface. The authors explored the impact of IVIg in complement-bacterial interactions in an attempt to determine the safety of IVIg formulations in natural immunity to bacteria and to expand their knowledge of the physiological mechanisms of IVIg. Using complement-sensitive and complement-resistant strains, the authors investigated the effect of IVIg on the binding of C3 to bacterial surfaces. In all cases, IVIg had no effect on the total amount of C3 bound to bacteria, whether the bacteria were directly activated by classical or altered by-pass complement. In addition, IVlg does not inhibit complement by